The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates

Biochemical and Biophysical Research Communications

Volumn 322, Issue 1, 2004, Pages 217-222

  Chander, Surinder K ^a   Purohit, Atul ^a   Woo, L W Lawrence ^b   Potter, Barry V L ^b   Reed, Michael J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

Carbonic anhydrase; Hormone replacement therapy; Oestrogen sulphamates; Oestrogens; Oral contraception; Steroid sulphatase

Indexed keywords

6 OXO 8,9,10,11 TETRAHYDRO 7H CYCLOHEPTA[C][1]BENZOPYRAN 3 O SULFAMATE; ESTROGEN DERIVATIVE; ESTRONE SULFAMATE; STERYL SULFATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG UPTAKE; ENZYME ACTIVITY; ERYTHROCYTE; ESTROGEN ACTIVITY; FEMALE; HYDROLYSIS; IN VITRO STUDY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; UTERUS GROWTH; UTERUS WEIGHT;

ANIMALS; COUMARINS; DRUG COMBINATIONS; ESTROGENS; ESTRONE; FEMALE; HOMEOSTASIS; ORGAN SIZE; OVARIECTOMY; RATS; RATS, WISTAR; STERYL-SULFATASE; SULFONAMIDES; SULFONIC ACIDS; UTERUS;

ANIMALIA;

EID: 4143072868     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.07.108     Document Type: Article

References (19)

1. R.A. Lobo, and D.L. Cassident Pharmacokinetics of oral 17β-estradiol J. Reprod. Med. 37 1992 77 84
2. H.H. Inhoffen, and H. Hohlweg Neue per os wirksame weibliche Keimdrusenhormonderivate Naturwiss 29 1938 96 100
3. M.J. Reed, K. Fotherby, and S.J. Steele Metabolism of ethynyloestradiol in man J. Endocrinol. 55 1972 351 361
4. C.A. Mashchak, R.A. Lobo, R. Dozono-Takano, P. Eggena, R.M. Nakamura, P.F. Brenner, and D.R. Mishell Comparisons of the pharmacodynamic properties of various estrogen formulations Am. J. Obstet. Gynecol. 144 1982 511 518
5. B. Von Schoultz, K. Carlstrom, L. Collste, A. Eriksson, P. Hennksson, A. Pousette, and R. Stege Estrogen therapy and liver function-metabolic effects of oral and parenteral administration The Prostate 14 1989 389 395
6. W. Elger, S. Schwarz, A. Hedden, G. Reddersen, and B. Schneider Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application J. Steroid Biochem. Mol. Biol. 55 1995 395 403
7. N.M. Howarth, A. Purohit, M.J. Reed, and B.V.L. Potter Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential J. Med. Chem. 37 1994 219 221
8. W. Elger, A. Barth, A. Hedden, G. Reddersen, P. Ritter, B. Schneider, J. Zuchner, E. Krahl, K. Muller, M. Oettel, and S. Schwarz Estrogen sulfamates: a new approach to oral estrogen therapy Reprod. Fertil. Dev. 13 2001 297 305
9. A. Purohit, G.J. Williams, N.M. Howarth, B.V.L. Potter, and M.J. Reed Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate Biochemistry 34 1995 11508 11514
10. L.W.L. Woo, A. Purohit, B. Malini, M.J. Reed, and B.V.L. Potter Potent active site-directed inhibition of steroid sulfatase by tricyclic coumarin-based sulphamates Chem. Biol. 7 2000 773 791
11. A. Purohit, G.J. Williams, C.J. Roberts, B.V.L. Potter, and M.J. Reed In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate Int. J. Cancer 63 1995 106 111
12. A. Purohit, L.W.L. Woo, B.V.L. Potter, and M.J. Reed In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE Cancer Res. 60 2000 3394 3396
13. W.-R.C.N.T. Zaveri, R. Peters, M. Tanabe, Y. Yamada, T. Toko, T. Asso, and K. Eshima A novel dual-targeted approach for the endocrine therapy and prevention of breast cancer: SRI 16158, a novel steroid sulfatase inhibitor/tissue-selective anti-estrogen Proc. Am. Assoc. Cancer Res., Adv. Breast Cancer Res. 2003
14. A. Purohit, V.A. Froome, D.Y. Wang, B.V.L. Potter, and M.J. Reed Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate J. Steroid Biochem. Mol. Biol. 62 1997 45 51
15. W. Elger, H.-J. Palme, and S. Schwarz Novel oestrogen sulphamates: a new approach to oral hormone therapy Exp. Opin. Invest. Drugs 7 1998 575 589
16. N. Vicker, Y.T. Ho, J. Robinson, L.W.L. Woo, A. Purohit, M.J. Reed, and B.V.L. Potter Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II Bioorg. Med. Chem. Lett. 13 2003 863 865
17. Y.T. Ho, A. Purohit, N. Vicker, S.P. Newman, J.J. Robinson, B.V.L. Potter, and M.J. Reed Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates Biochem. Biophys. Res. Commun. 305 2003 909 914
18. F. Abbate, J.-Y. Winum, B.V.L. Potter, A. Casini, J.-L. Montero, A. Scozzafava, and C.T. Supuran Carbonic anhydrase inhibitors: X ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase Bioorg. Med. Chem. Lett. 14 2004 231 234
19. U.G. Sahm, G.J. Williams, A. Purohit, M.I. Hidalgo Aragones, D. Parish, M.J. Reed, B.V.L. Potter, and C.W. Poulton Development of an oral formulation for oestrone 3-O-sulphamate, a potent sulphatase inhibitor Pharm. Sci. 2 1996 17 20